In a significant development, Lupin Limited, a global pharmaceutical leader, announced a non-exclusive patent licence agreement with Takeda Pharmaceutical Company Limited to commercialise Vonoprazan Tablets in the Indian market. The medication, set to be marketed under Lupin’s brand name Lupivon, will be available in two strengths—10 mg and 20 mg—bringing a novel gastrointestinal drug to […]
LupinLife, the consumer healthcare division of global pharmaceutical giant Lupin Limited, announced a significant entry into the Indian liquid laxative market with the launch of Softovac Liquifibre. This innovative product marks a new chapter in digestive health solutions, offering a 100% Ayurvedic liquid laxative formulated with natural actives like Isabgol fibre, Sonamukhi, Harad, Mulethi, Saunf, […]
In a move that has set the pharmaceutical industry abuzz, global pharma titan Lupin Limited has revealed the acquisition of five key legacy brands, zeroing in on pivotal therapy areas like Gastroenterology, Urology, and Anti-infectives. This acquisition, inked with Menarini, encompassing both A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings Pte. Ltd., includes […]
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH. These brands, which Lupin has been marketing since 2015 under a co-marketing arrangement, come with the added bonus of trademark rights. India grapples […]
Indian cardiac digital therapeutics entity, Lupin Digital Health (LDH), marked another achievement with the unveiling of its Lyfe Digital Heart Failure Clinic. Designed to cater to the escalating 10 million-plus heart failure patients in India, this avant-garde e-clinic blends the convenience of home-based care with the precision of in-clinic consultations. Addressing India’s Cardiac Health Concerns […]
Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is the first biosimilar developed for Eli Lilly and Company’s Cetuximab, a monoclonal antibody medication used in the treatment of various types of cancer, including head and neck cancer and metastatic […]